Turku-based drug delivery company DelSiTech Ltd, a portfolio company of Innofinance, has entered into a license agreement with Bayer Innovation GmbH. The deal gives Bayer the exclusive rights to use the DelSiTech ® drug delivery technology for fiber applications in the fields of wound care and certain other applications.
Deal is an exit for minority shareholder Antea, which invested in the company in 2015
Deal is GP's sixth investment from its £100m Impact Fund, which targets profitable businesses making a positive impact
Matt Cashion joined Pantheon's New York office earlier in October
Deal is the ninth investment from Tenzing's debut fund, with its successor yet to deploy